Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Radionuclide drug treatment planning goes to next level with 3-D patient models

Radionuclide drug treatment planning goes to next level with 3-D patient models

PSMA enzyme could become hallmark of new generation of biomarkers for prostate cancer treatment

PSMA enzyme could become hallmark of new generation of biomarkers for prostate cancer treatment

EORTC BOS 2 trial to test efficacy of adding bevacizumab to peri-operative FOLFOX 4 chemotherapy

EORTC BOS 2 trial to test efficacy of adding bevacizumab to peri-operative FOLFOX 4 chemotherapy

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Study investigates gene expression signature to predict response to bevacizumab

Study investigates gene expression signature to predict response to bevacizumab

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer

New therapy for lung cancer produces manageable side effects

New therapy for lung cancer produces manageable side effects

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Researchers discover potential biomarkers to identify patients with head and neck cancer

Researchers discover potential biomarkers to identify patients with head and neck cancer

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13 drug induces antidepressant results without street drug side effects

PharmAthene announces lifting of clinical hold on proposed SparVax Phase II study

PharmAthene announces lifting of clinical hold on proposed SparVax Phase II study

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Common sugar molecule promising target for development of broad-spectrum vaccine

Common sugar molecule promising target for development of broad-spectrum vaccine

Lab-based skin test eliminates risk of adverse reactions to new drugs, cosmetics

Lab-based skin test eliminates risk of adverse reactions to new drugs, cosmetics

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.